BIOPHARMX CORPORATION (NYSEMKT:BPMX) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition
On March 23, 2017, BioPharmX Corporation (“Company”) issued a press release announcing its financial results and certain other information for the quarterly and annual periods ended January 31, 2017. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by the Company with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
99.1 Press release issued by BioPharmX Corporation regarding its financial results for the quarterly and annual periods ended January 31, 2017, dated March 23, 2017.